News and Announcements
Riccardo Canevari of Radiopharm Theranostics (ASX:RAD)
- Published December 06, 2022 6:49AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Radiopharm Theranostics (ASX:RAD) is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The company has a pipeline of four distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer, from some of the world’s leading universities and institutes.
Watch this interview with CEO Riccardo Canevari as he discusses how they approach oncology with their unique processes.
Executive Interviews
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
